AI Article Synopsis
- The study investigated the effects of fotemustine (FM) and dacarbazine (DTIC) on human HTB140 melanoma cells after proton irradiation, looking at varying drug concentrations and irradiation doses.
- After treatment with both drugs and proton irradiation, cell viability was assessed over time, showing that increased drug concentration or irradiation led to about 60% cell inactivation.
- Results indicated that HTB140 cells are more resistant to proton therapy compared to the alkylating agents tested, and combining FM or DTIC with proton irradiation didn't significantly enhance the effectiveness compared to using each treatment alone.
Article Abstract
Viability of human HTB140 melanoma cells after being exposed to fotemustine (FM) and dacarbazine (DTIC) as well as to proton irradiation was studied. Effects of 100 and 250 microM drugs were assessed after incubation of 6, 24, 48, 72, and 96 h. Irradiations were performed with 62 MeV therapeutic protons, delivering to the cell monolayer single doses of 2, 4, 8, 12, and 16 Gy. Viability was evaluated 7 days after irradiation. Inactivation level was estimated using microtetrasolium (MTT) and sulforhodamine B (SRB) assays. Combined effects of each drug and protons, were carried out using the same drug concentrations. Proton doses applied were those used in therapy, that is, 12 and 16 Gy. With the increase of drug concentration or irradiation dose, level of cell inactivation reached approximately 60%, 48 h after drug treatment or 7 days after irradiation at 16 Gy. Considering the rate of drug concentrations used, as well as the level of doses applied, it appears that HTB140 cells are more resistant to proton irradiation than to alkylating agents tested. The combined treatment with FM or DTIC and protons did not show significant changes of cell viability as compared to the effects of single agents. Since the time point for measuring cumulative effects of drug and irradiation was 48 h post irradiation, it seems that the obtained level of viability could be attributed primarily to the effects of drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1196/annals.1397.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis.
Radiat Oncol
January 2025
The First School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou, 730000, China.
Background: Proton beam therapy (PBT) has been gradually introduced for treating choroidal melanoma. This study systematically reviewed clinical reports to evaluate the efficacy and safety of PBT in choroidal melanoma patients.
Methods: This systematic review included all the primary studies involving PBT for choroidal melanoma patients through April 2024.
Evaluation of machine learning models for predicting xerostomia in adults with head and neck cancer during proton and heavy ion radiotherapy.
Radiother Oncol
January 2025
Department of Nursing, Shanghai Proton and Heavy Ion Center, Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai 201315 China. Electronic address:
Background And Purpose: Few studies have examined the factors associated with xerostomia during proton and carbon ion radiotherapy for head and neck cancer (HNC), which are reported to have fewer toxic effects compared to traditional photon-based radiotherapy. This study aims to evaluate the performance of machine learning approaches in predicting grade 2 + xerostomia in adults with HNC receiving proton and carbon ion radiotherapy.
Materials And Methods: A retrospective study involving 1,769 adults with HNC who completed proton or carbon ion radiotherapy was conducted.
A multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy.
Breast
January 2025
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China; Shanghai Key Laboratory of Proton Therapy, Shanghai, 201801, China. Electronic address:
Purpose: This study aims to assess whether dual anti-HER2 therapy with trastuzumab and pertuzumab increases early cardiac toxicity compared to trastuzumab alone in breast cancer (BC) patients receiving postoperative radiation therapy (RT).
Methods: Consecutive operable BC patients receiving postoperative RT and trastuzumab with or without pertuzumab between January 2017 and September 2020 at seven tertiary hospitals in China were retrospectively reviewed. Cardiac examinations included echocardiography, electrocardiogram (ECG), NT-proBNP, and cTnI at baseline before RT and during the follow-up.
Proton dose deposition in heterogeneous media: A TOPAS Monte Carlo simulation study.
Appl Radiat Isot
January 2025
Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, 230031, China. Electronic address:
This study investigated the influence of tissue electron density on proton beam dose distribution using TOPAS Monte Carlo simulation. Heterogeneous tissue models composed of 14 materials were constructed to simulate the dose deposition process of a 169.23 MeV proton beam.
View Article and Find Full Text PDFDefining the Optimal Dose for 3-Dimensional Conformal Accelerated Partial Breast Irradiation: 15-Year Follow-Up of a Dose-Escalation Trial.
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Purpose: Randomized trials have demonstrated similar local tumor control in patients treated with accelerated partial-breast irradiation (APBI) compared with whole-breast irradiation. However, the optimal APBI dose for maximizing tumor control and minimizing toxicity is uncertain.
Methods And Materials: We enrolled patients ≥18 years of age with grade 1 or 2 ductal carcinoma in situ or stage I invasive breast cancer and resection margins ≥2 mm between 2003 and 2011 to a sequential dose-escalation trial using 3-dimensional conformal external beam APBI giving twice daily 4 Gy fractions with total doses of 32 Gy, 36 Gy, and 40 Gy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!